Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.32 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | GAA | P10253 | 2/20 | 0.32 |
| ▸ | MAPT | P10636 | 2/20 | 0.32 |
| ▸ | NPC1 | O15118 | 1/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.32 |
| ▸ | PPARA | Q07869 | 1/20 | 0.31 |
| ▸ | RARA | P10276 | 1/20 | 0.30 |
| ▸ | RARB | P10826 | 1/20 | 0.30 |
| ▸ | RARG | P13631 | 1/20 | 0.30 |
| ▸ | MEN1 | O00255 | 1/20 | 0.30 |
| ▸ | LMNA | P02545 | 1/20 | 0.30 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10237919 | 0.88 | RAB9A (0.38) | KDM4EALDH1A1GAAMAPTNPC1 | |
| SCHEMBL10238020 | 0.86 | PTGS2 (0.41) | KDM4EALDH1A1MAPTPPARALMNA | |
| SCHEMBL10237965 | 0.86 | RARA (0.31) | KDM4EALDH1A1GAAMAPTRARA | |
| SCHEMBL10237934 | 0.86 | RAB9A (0.40) | KDM4EALDH1A1GAAMAPTNPC1 | |
| SCHEMBL10237930 | 0.86 | NPC1 (0.34) | MAPTNPC1RARARARBRARG | |
| SCHEMBL10238017 | 0.86 | ALDH1A1 (0.41) | KDM4EALDH1A1GAAMAPTNPC1 | |
| SCHEMBL10238025 | 0.85 | NPC1 (0.43) | KDM4EALDH1A1GAAMAPTNPC1 | |
| SCHEMBL10238159 | 0.84 | L3MBTL1 (0.32) | L3MBTL1 | |
| SCHEMBL10238024 | 0.84 | ALOX5 (0.41) | KDM4EALDH1A1GAAMAPTNPC1 | |
| SCHEMBL10238096 | 0.84 | NPC1 (0.40) | KDM4EALDH1A1MAPTNPC1RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2176222-B1 | NOVEL HERBICIDES | SYNGENTA LTD (GB) | 2014-11-05 | — | — | EP | disclosed |
| US-8541594-B2 | — | — | 2013-09-24 | — | — | US | disclosed |
| US-8541594-B2 | — | — | 2013-09-24 | — | — | US | disclosed |
| US-20120040826-A1 | NOVEL HERBICIDES | SYNGENTA LIMITED (GB) | 2012-02-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120040826-A1 | NOVEL HERBICIDES | DDT, HDHD5, DDC | KDM4E 1609/4885ALDH1A1 294/4885GAA 1293/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.